Fig. 3.
Effects of coagulation factor concentrates (CFCs) on dabigatran anticoagulation as measured by (A) activated partial thromboplastin time (aPTT), (B) prothrombin time (PT), (C) thrombin time (TT), and (D) ecarin clotting time (ECT). Assay results at each time point for dabigatran alone and each CFC are reported as the ratio of the baseline value (time 0). The dabigatran coagulation level just before CFC administration (i.e., peak dabigatran) is the upper horizontal dotted line. The lower dotted line shows control values after administration of vehicle. Values are shown as mean ± SEM (n = 5–8 animals per group). *P < 0.05 versus dabigatran alone at each time point. DE = dabigatran etexilate; FEIBA = Factor Eight Inhibitor Bypassing Activity. Bebulin (Baxter BioScience, Westlake Village, CA); Beriplex (CSL Behring, Marburg, Germany); FEIBA (Baxter AG, Vienna, Austria); NovoSeven (NovoNordisk, Bagsværd, Denmark); Octaplex (Octapharma AG, Lachen, Switzerland); Profilnine (Grifols Biologicals Inc., Los Angeles, CA).